Lisinopril Side Effects: Incidence Rates Across Clinical Trials

This article is pending qualified medical review. Several numeric claims in earlier versions of this page could not be traced to a verifiable source and have been removed or reframed below as general ranges pending confirmation against the primary literature.

Lisinopril (brand names Zestril and Prinivil, generic name lisinopril) is an angiotensin-converting enzyme (ACE) inhibitor approved by the FDA for hypertension, heart failure, and improving survival after acute myocardial infarction. It is not the same drug as an angiotensin receptor blocker (ARB) such as losartan, and it should not be confused with combination products that pair lisinopril with hydrochlorothiazide.

The useful question for a patient or clinician is rarely "does lisinopril cause side effects." It does, like every ACE inhibitor. The more useful question is which side effects are dose-related and reversible with a simple adjustment, which require lab monitoring rather than drug discontinuation, and which are rare but dangerous enough that the drug should never be restarted. Those three categories call for different actions, and conflating them leads either to unnecessary drug discontinuation or to missed warning signs.

What is established, what is plausible, and what is not established

Established: Lisinopril and other ACE inhibitors cause a dry, non-productive cough in a meaningful minority of patients, driven by bradykinin accumulation rather than allergy. Angioedema is a rare but recognized, sometimes fatal, class effect. ACE inhibitors reduce aldosterone and can raise serum potassium, more so in chronic kidney disease, diabetes, or with concurrent potassium-sparing drugs. First-dose and early hypotension is more common in heart failure and post-MI populations than in uncomplicated hypertension. ACE inhibitors are contraindicated in pregnancy because of fetal renal toxicity.

Plausible but not settled by strong evidence on this page: Precise numeric incidence rates for many of these effects (for example, an exact percentage for cough in a specific trial, or an exact odds ratio for a drug interaction) were cited in earlier drafts with citation numbers that do not reliably map to the papers named. Those exact figures should be treated as unverified until an editor confirms them against the named trial or the current FDA label.

Not established from the material available here: A specific genetic test guiding ACE inhibitor selection, a specific numeric risk multiplier for individual drug interactions, and precise dose-by-dose discontinuation percentages from named trials. These would need direct verification against the original publications before being restated as fact.

Lisinopril's core adverse-effect profile in one paragraph

Lisinopril's most common adverse effects are dizziness, headache, and hypotension-related symptoms, all of which track with its blood-pressure-lowering mechanism and are most pronounced in heart failure and post-MI patients rather than in routine hypertension treatment. Dry cough, caused by bradykinin buildup rather than allergy, is the single most common reason patients switch away from an ACE inhibitor, and it resolves after stopping the drug. Angioedema and hyperkalemia are less common but more consequential: angioedema can obstruct the airway, and hyperkalemia risk rises sharply with kidney disease, diabetes, or concurrent potassium-sparing medications. The FDA-approved lisinopril prescribing information lists these categories among the adverse reactions observed in controlled trials.

Cough: why it happens and what to do about it

ACE inhibition slows the breakdown of bradykinin and substance P in the respiratory tract, and elevated bradykinin is the accepted mechanism for ACE inhibitor cough. Published incidence estimates for ACE inhibitor cough vary widely across studies, generally described in the pulmonary and hypertension literature as ranging from roughly 5% to 20% of treated patients, with higher rates reported in cohorts of East Asian descent. These ranges are widely cited but the specific meta-analysis and cohort study numbers referenced in earlier versions of this page require direct verification before being restated as precise figures.

Cough typically begins within the first few weeks of therapy and resolves within days to a few weeks of stopping the drug. Switching to an ARB is the standard clinical approach when a patient needs ongoing renin-angiotensin system blockade but cannot tolerate the cough, because ARBs do not raise bradykinin the same way ACE inhibitors do. Systematic reviews comparing ARB-associated cough to placebo have generally found rates close to placebo, though the exact review and its confidence interval should be confirmed with a current search of the Cochrane Library rather than cited from a single unverified link.

Angioedema: rare, but the one side effect that changes management permanently

Angioedema from lisinopril is bradykinin-mediated swelling of the face, lips, tongue, or larynx, and in some cases the intestinal wall. Laryngeal involvement is a medical emergency because it can obstruct the airway. FDA labeling and post-market surveillance describe angioedema as an uncommon event, generally cited in the range of a few tenths of a percent of treated patients, with the first month of therapy carrying the highest risk. Observational data have also described a higher incidence in Black patients compared with White patients, consistent with findings described in large, government-funded comparative hypertension trials, though the exact relative-risk figure attributed to such trials in earlier drafts of this page should be confirmed against the original publication before being restated as a precise number.

A single episode of ACE inhibitor angioedema is generally treated as a reason to avoid all ACE inhibitors going forward, because the mechanism is a class effect rather than specific to one drug. This is a clinical judgment reflected in allergy and immunology practice guidance rather than a number that needs verification; the decision itself, not a statistic, is the actionable point for readers.

Hyperkalemia: who needs monitoring and how often

ACE inhibitors reduce aldosterone secretion, which can impair the kidney's ability to excrete potassium. This risk is low in patients with normal kidney function and rises meaningfully in chronic kidney disease, diabetes, heart failure, or with concurrent use of potassium-sparing diuretics, potassium supplements, or NSAIDs. An ALLHAT-based analysis of incident hyperkalemia and hypokalemia in treated hypertensive patients examined the clinical significance of these electrolyte shifts in a large hypertensive trial population; readers and editors should confirm the exact incidence figures in that paper before citing a specific percentage on this page.

Heart failure guidelines from cardiology societies generally recommend checking serum potassium and creatinine within one to two weeks of starting or increasing an ACE inhibitor dose, and again after any subsequent dose change. A potassium level clearly above the normal range warrants dose reduction; a level in the danger range warrants holding the drug and same-day clinical evaluation rather than waiting for a routine follow-up.

Hypotension: dose- and setting-dependent

Symptomatic hypotension is more common when lisinopril is started in heart failure or immediately after a myocardial infarction than when it is started for uncomplicated hypertension, because these patients often have lower baseline blood pressure and are more likely to be on concurrent diuretics. Trials in these higher-risk populations have generally reported hypotension in a meaningfully higher share of patients than trials in routine hypertension, though the exact percentages attributed to specific trials such as ATLAS and GISSI-3 in earlier drafts require verification against the original publications before being treated as settled figures.

Starting at a low dose and titrating upward over weeks, particularly in patients with a systolic blood pressure under 100 mmHg or significant volume depletion, is the standard approach to reducing first-dose hypotension. This is a dosing principle, not an individualized dosing instruction, and any specific starting dose should come from the prescribing clinician.

Kidney effects: an expected small creatinine rise versus a warning sign

Lisinopril lowers pressure inside the glomerulus by dilating the efferent arteriole, which is protective over the long term in diabetic kidney disease but can acutely lower the glomerular filtration rate in patients with renal artery stenosis or significant volume depletion. A modest early rise in creatinine, generally described in kidney-disease guidance as up to roughly 30% above baseline, is usually considered acceptable and not a reason to stop the drug on its own. A larger rise warrants investigation for renal artery stenosis or dehydration before continuing treatment. A separate ALLHAT report specifically comparing renal outcomes among ACE inhibitor, calcium channel blocker, and diuretic-treated patients is a relevant primary source for this comparison, though its specific incidence numbers should be pulled directly from the paper rather than restated from memory.

The FDA's Adverse Event Reporting System (FAERS) is a spontaneous-report database, useful for signal detection but not for calculating true incidence, since reporting is voluntary and causality is not confirmed. The FAERS public dashboard can be searched directly for lisinopril-associated reports, but any reporting-odds-ratio figure quoted from it should be pulled fresh from the dashboard rather than treated as a fixed historical number, since the dashboard updates continuously.

Less common effects worth knowing about

Altered or metallic taste (dysgeusia) has been described in a small share of patients and is thought to relate to zinc chelation by the ACE inhibitor structure; it typically improves with dose reduction. Skin rash is an uncommon but recognized reaction. Severe hematologic reactions such as agranulocytosis and serious liver injury including cholestatic jaundice are rare, reported mainly in post-marketing case reports rather than large trials, and the FDA label advises white blood cell monitoring in patients with underlying autoimmune conditions such as lupus. Intestinal (visceral) angioedema, presenting as crampy abdominal pain and vomiting without visible facial swelling, is easy to misdiagnose as an acute abdomen and has been described in case series as an under-recognized cause of unexplained abdominal pain in ACE inhibitor users. Exact frequency figures for these rare events should be treated as approximate order-of-magnitude descriptions rather than precise rates.

Pregnancy: an absolute contraindication, not a relative one

ACE inhibitors, including lisinopril, carry a boxed warning for fetal toxicity. Exposure during the second and third trimesters is associated with fetal renal problems, low amniotic fluid, skull and limb abnormalities, and can be fatal to the fetus. Some retrospective data have also linked first-trimester exposure to a higher rate of congenital cardiac malformations, though the exact odds ratio should be confirmed against the primary study before being quoted precisely. Any person who becomes pregnant while taking lisinopril should contact their prescriber promptly to discuss switching to a pregnancy-appropriate antihypertensive; this is a decision for the treating clinician, not a self-directed dose change.

Differences in response and risk across populations

ALLHAT and related hypertension trial data have described a pattern in which Black patients treated with ACE inhibitor monotherapy had less blood pressure reduction and a higher rate of certain outcomes, including stroke and angioedema, compared with those treated with a thiazide-type diuretic. This is generally attributed to lower average renin-angiotensin system activity in this population reducing ACE inhibitor efficacy as monotherapy, rather than to a direct toxic effect of the drug itself. Current hypertension guidelines from major cardiology societies generally favor thiazide-type diuretics or calcium channel blockers over ACE inhibitors as first-line monotherapy in Black patients without a compelling separate indication such as heart failure or chronic kidney disease, though readers should confirm the current guideline text directly rather than rely on a quoted excerpt here, since guideline language is periodically updated.

Genetic variation in the ACE gene has been proposed as a contributor to individual differences in cough susceptibility across racial groups. This is an area of active research rather than a settled clinical tool, and no major guideline currently recommends genetic testing before starting an ACE inhibitor.

Drug interactions that change the risk-benefit picture

NSAIDs can blunt lisinopril's blood-pressure-lowering effect and increase the risk of acute kidney injury when combined, particularly in volume-depleted or older patients. Potassium-sparing diuretics, potassium supplements, and, separately, aliskiren (a direct renin inhibitor) each raise the risk of hyperkalemia or renal adverse events when combined with an ACE inhibitor; combining aliskiren with an ACE inhibitor in patients with diabetes or reduced kidney function is specifically discouraged based on trial data showing harm without added cardiovascular benefit. Lithium levels can rise when combined with an ACE inhibitor because of reduced renal lithium clearance, and lithium level monitoring is reasonable after starting or adjusting lisinopril in a patient already on lithium. None of these interaction risks should be managed by self-adjusting a dose; they require the prescribing clinician's input.

When to seek urgent care versus when to call the prescriber

Facial, lip, tongue, or throat swelling, difficulty breathing or swallowing, or a voice change after starting lisinopril is an emergency and warrants calling emergency services or going to an emergency department immediately, not waiting for a callback. Severe abdominal pain with vomiting in someone on an ACE inhibitor should also prompt urgent evaluation, since it can be intestinal angioedema rather than a routine stomach bug. Persistent dry cough, mild dizziness on standing, or a routine lab showing a modest creatinine or potassium change are reasons to contact the prescriber for a non-urgent conversation about dose adjustment or a possible switch to an ARB, not reasons to stop the drug abruptly without guidance, particularly in heart failure or post-MI patients where the drug provides a mortality benefit.

A decision framework for a new symptom on lisinopril

This tool cannot diagnose lisinopril side effects and is not a substitute for medical evaluation by a healthcare provider. It helps you determine how quickly a new symptom warrants professional attention.

The pattern underneath this table is simple: airway or breathing symptoms are never a "wait and see," lab abnormalities are almost always a "call and discuss," and mechanism-predictable symptoms like cough or positional dizziness are usually manageable without stopping a drug that, in heart failure and post-MI patients, has a documented mortality benefit.

What this page cannot tell you

This article cannot tell an individual reader whether a symptom they are experiencing is caused by lisinopril, whether their potassium or creatinine trend is dangerous, or what dose adjustment is appropriate for them. Those judgments require a clinician who has the person's labs, other medications, and medical history. Several precise incidence percentages that appeared in earlier versions of this content have been removed or reframed here as ranges because they could not be confirmed against the named source; an editor with access to the original trial publications should verify any number before it is republished as a specific statistic.